SOURCE: Mount Tam Biotechnologies

Mount Tam Biotechnologies

March 24, 2016 12:30 ET

Mount Tam Biotechnologies, Inc. Announces the Appointment of Richard Marshak as CEO

NOVATO, CA--(Marketwired - Mar 24, 2016) -  Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM) is pleased to announce that Dr. Richard Marshak has assumed the role of CEO, effective immediately. Dr. Marshak succeeds interim CEO Dr. Tim Powers, who remains on the Board of Directors and continues to oversee product development as Chief Scientific Officer.

Brian Kennedy, Ph.D., Chairman of Mount Tam, and CEO of the Buck Institute for Research on Aging, said, "We are excited to bring Richard on board as his skills and experience are a strong complement to our core capabilities. We see this as a critical next step for Mount Tam, and we look forward to accelerating our path to success. By bringing Richard on as CEO we expect to fully leverage the substantial Mount Tam IP portfolio, its collaboration with the Buck Institute, and the exciting clinical opportunities for mTOR inhibitors."

According to Dr. Marshak, "Taking on the role of CEO at Mount Tam is a truly exciting prospect. With a strong lead compound, solid IP portfolio and a platform to generate novel compounds to address areas of high unmet need, Mount Tam is poised for growth. In addition, the research collaboration between the Buck Institute and Mount Tam to advance our understanding of mTOR inhibition is a real differentiating factor, and one that I believe will help us further strengthen our solid scientific foundation. We have outlined our course of action and key milestones for 2016 and 2017, and I look forward to working with this great team to bring new medicines to market that improve patient's lives."

Dr. Marshak brings 18 years of pharmaceutical experience across a wide range of leadership roles. At Abbott/Abbvie, he occupied roles of increasing responsibility in their Pharmaceutical Products Group including product marketing, business development, therapeutic area general manager and general manager, global alliance management and strategic planning. Since leaving Abbvie he has served as strategic consultant to a range of biotech companies, helping to guide critical decisions including product development, corporate strategy, business development and commercialization strategies. Dr. Marshak holds VMD and BA degrees from the University of Pennsylvania and an MBA from the University of Chicago's Booth School of Business.

About Mount Tam Biotechnologies, Inc.

Formed on World Lupus Day 2014, Mount Tam Biotechnologies, Inc. was established to develop, optimize and bring to market leading medical compounds to better the health and well being of millions of people who have been affected by autoimmune diseases. The organization's most advanced product focuses on the treatment of systemic lupus erythematosus (SLE). 

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets, which are focused on autoimmune diseases, are highly target-specific polyketides--a class of compounds with an extremely successful track record with the F.D.A. drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.

Mount Tam is applying its first and most advanced asset, TAM-01, to the Investigational New Drug (IND) application phase of the FDA. It has already completed extensive non-GLP pre-clinical development. The primary focus is to develop TAM-01 for the treatment of systemic lupus erythematosus (SLE) in an expanding orphan drug market. Mount Tam will use the R&D conducted on TAM-01 as the core science for additional assets, including its second product known as TAM-02, which is currently focused on multiple sclerosis (MS).

For more information visit www.MountTamBiotech.com

Contact Information

  • Investor and Media Contact:

    David R. Wells
    Interim Chief Financial Officer
    (310) 800-7175